Mitsubishi UFJ Trust & Banking Corp Sells 3,657 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Mitsubishi UFJ Trust & Banking Corp decreased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 3.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 92,009 shares of the biotechnology company’s stock after selling 3,657 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Exelixis were worth $3,064,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Tri Ri Asset Management Corp bought a new position in Exelixis during the 3rd quarter worth $4,396,000. Blue Trust Inc. grew its stake in shares of Exelixis by 134.7% in the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 8,208 shares in the last quarter. Range Financial Group LLC bought a new position in Exelixis during the fourth quarter worth about $994,000. FMR LLC boosted its holdings in Exelixis by 6.1% in the 3rd quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after purchasing an additional 140,568 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Exelixis by 82.1% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock worth $52,884,000 after purchasing an additional 704,786 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of recent research reports. Guggenheim restated a “buy” rating and set a $42.00 price objective on shares of Exelixis in a research note on Wednesday, February 12th. Royal Bank of Canada raised their price target on Exelixis from $38.00 to $40.00 and gave the stock an “outperform” rating in a research report on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday, March 27th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 19th. Finally, JMP Securities reissued a “market outperform” rating and set a $41.00 price target on shares of Exelixis in a report on Thursday, January 23rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Insider Buying and Selling at Exelixis

In related news, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the transaction, the executive vice president now owns 341,028 shares in the company, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bob Oliver sold 18,647 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the sale, the director now directly owns 33,514 shares of the company’s stock, valued at $1,248,396.50. This represents a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock worth $5,177,234 over the last three months. 2.85% of the stock is currently owned by insiders.

Exelixis Stock Up 0.6 %

Shares of NASDAQ EXEL opened at $36.92 on Tuesday. The company has a market capitalization of $10.33 billion, a PE ratio of 20.86, a PEG ratio of 1.13 and a beta of 0.57. The stock’s 50 day moving average price is $35.72 and its 200-day moving average price is $33.39. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.